



10/035,211.



**IN THE CLAIMS:**


Please enter the following new claims:

45. A vitamin D<sub>3</sub> derivatives expressed by the following general formula [1] or pharmaceutically permissible solvates thereof,



{wherein, R<sub>01</sub> and R<sub>02</sub> are each independently a hydrogen atom, a trimethylsilyl group, a triethylsilyl group, a t-butyltrimethylsilyl group, an acetyl group, a methoxymethyl group or a tetrahydro-4H-pyran-2-yl group;

Z is represented by formula (1-5),



(1-5)

[in the above formula (1-5),

R<sub>51</sub> expresses -CONR<sub>511</sub>R<sub>512</sub>, -COR<sub>513</sub> or -C(OH)R<sub>514</sub>R<sub>515</sub>, wherein R<sub>511</sub> and R<sub>512</sub> are identical to or different from each other, and they are a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group, or both the members together express a nitrogen-containing C<sub>3</sub>-C<sub>8</sub> alkyl ring or a morpholino group in cooperation with the nitrogen atom to which they are bonded; and R<sub>513</sub>, R<sub>514</sub> and R<sub>515</sub> are identical to or different from each other, and they express a C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sub>52</sub> expresses a methyl group, an ethyl group, a trifluoromethyl group or a pentafluoroethyl group.

46. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>01</sub> and R<sub>02</sub> are both hydrogen atoms.

47. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>51</sub> is -CONR<sub>511</sub>R<sub>512</sub> or -COR<sub>513</sub>.

48. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>51</sub> is -CONR<sub>511</sub>R<sub>512</sub>.

49. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>51</sub> is -COR<sub>513</sub>.

50. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>51</sub> is -CONR<sub>511</sub>R<sub>512</sub>, and R<sub>511</sub> and R<sub>512</sub> are identical to or different from each other, and they are a methyl group or an ethyl group, or

are identical to or different from each other, and they are a methyl group or an ethyl group, or both the members together express an aziridine, pyrrolidine, piperidine or morpholino ring in cooperation with the nitrogen atom to which they are bonded.

51. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>51</sub> is COR<sub>513</sub>, and R<sub>513</sub> is a methyl group or an ethyl group.

52. A vitamin D<sub>3</sub> derivative or a pharmaceutically permissible solvate thereof described in Claim 45, wherein, in the above formula (1), R<sub>52</sub> is a methyl group.

53. A pharmaceutical composition composed of a vitamin D<sub>3</sub> derivative or pharmaceutically permissible solvate thereof described in Claim 45, and a pharmaceutically permissible carrier.

**IN THE ABSTRACT OF DISCLOSURE:**

**Please delete the present Abstract of the Disclosure and replace it with the following new Abstract of the Disclosure:**

Compounds expressed by the following general formula (1),